28 results on '"Zhu, Xiao-Dong"'
Search Results
2. Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study
- Author
-
Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Xu, Bin, Wu, Dong, Ji, Yuan, Chen, Ling-Li, Song, Tian-Qiang, Zhang, Wei, Zeng, Zhi-Ming, Huang, Hua-Sheng, Wang, Kui, Huang, Lan-Qing, Chen, Yong-Jun, Yang, Yu-Chen, Zhou, Le-Du, Long, Guo, Zhao, Hai-Tao, Wang, Yun-Chao, Ge, Ning-Ling, Chen, Yi, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, and Sun, Hui-Chuan
- Published
- 2023
- Full Text
- View/download PDF
3. Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
- Author
-
Liu, Xue-Feng, Zhu, Xiao-Dong, Feng, Long-Hai, Li, Xiao-Long, Xu, Bin, Li, Kang-Shuai, Xiao, Nan, Lei, Ming, Sun, Hui-Chuan, and Tang, Zhao-You
- Published
- 2022
- Full Text
- View/download PDF
4. An mALBI-Child–Pugh-based nomogram for predicting post-hepatectomy liver failure grade B–C in patients with huge hepatocellular carcinoma: a multi-institutional study
- Author
-
Xu, Ming-Hao, Xu, Bin, Zhou, Chen-Hao, Xue, Zhong, Chen, Zhao-Shuo, Xu, Wen-Xin, Huang, Cheng, Zhu, Xiao-Dong, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan, and Shen, Ying-Hao
- Published
- 2022
- Full Text
- View/download PDF
5. Neutrophil CD64 index for diagnosis of infectious disease in the pediatric ICU: a single-center prospective study
- Author
-
Cao, Lu-Lu, Wang, Wei-Wei, Zhao, Li, Li, Ji-Ru, Kong, Xiang-Mei, Zhu, Yue-Niu, and Zhu, Xiao-Dong
- Published
- 2022
- Full Text
- View/download PDF
6. A nomogram based on circulating CD8+ T cell and platelet-to-lymphocyte ratio to predict overall survival of patients with locally advanced nasopharyngeal carcinoma.
- Author
-
Yan, Chang, Yang, Guohai, Zhang, Chaojun, Chen, KaiHua, Sun, Yongchu, Liang, Zhongguo, Lai, Lin, Li, Ling, Qu, Song, and Zhu, Xiao-Dong
- Subjects
PLATELET lymphocyte ratio ,LYMPHOCYTE subsets ,OVERALL survival ,DECISION making ,SURVIVAL rate - Abstract
Purpose: To explore the influence of circulating lymphocyte subsets, serum markers, clinical factors, and their impact on overall survival (OS) in locally advanced nasopharyngeal carcinoma (LA-NPC). Additionally, to construct a nomogram predicting OS for LA-NPC patients using independent prognostic factors. Methods: A total of 530 patients with LA-NPC were included in this study. In the training cohort, Cox regression analysis was utilized to identify independent prognostic factors, which were then integrated into the nomogram. The concordance index (C-index) was calculated for both training and validation cohorts. Schoenfeld residual analysis, calibration curves, and decision curve analysis (DCA) were employed to evaluate the nomogram. Kaplan-Meier methods was performed based on risk stratification using the nomogram. Results: A total of 530 LA-NPC patients were included. Multivariate Cox regression analysis revealed that the circulating CD8
+ T cell, platelet-to-lymphocyte ratio (PLR), lactate dehydrogenase (LDH), albumin (ALB), gender, and clinical stage were independent prognostic factors for LA-NPC (p < 0.05). Schoenfeld residual analysis indicated overall satisfaction of the proportional hazards assumption for the Cox regression model. The C-index of the nomogram was 0.724 (95% CI: 0.669–0.779) for the training cohort and 0.718 (95% CI: 0.636-0.800) for the validation cohort. Calibration curves demonstrated good correlation between the model and actual survival outcomes. DCA confirmed the clinical utility enhancement of the nomogram over the TNM staging system. Significant differences were observed in OS among different risk stratifications. Conclusion: Circulating CD8+ T cell, PLR, LDH, ALB, gender and clinical stage are independent prognostic factors for LA-NPC. The nomogram and risk stratification constructed in this study effectively predict OS in LA-NPC. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
- Author
-
Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Wu, Dong, Ji, Yuan, Ge, Ning-Ling, Chen, Ling-Li, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, and Sun, Hui-Chuan
- Published
- 2021
- Full Text
- View/download PDF
8. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
- Author
-
Zhang, Shi-Zhe, Zhu, Xiao-Dong, Feng, Long-Hai, Li, Xiao-Long, Liu, Xue-Feng, Sun, Hui-Chuan, and Tang, Zhao-You
- Published
- 2021
- Full Text
- View/download PDF
9. Apolipoprotein D alleviates glucocorticoid-induced osteogenesis suppression in bone marrow mesenchymal stem cells via the PI3K/Akt pathway
- Author
-
Yu, Rong-Hua, Zhang, Xiang-yang, Xu, Wei, Li, Zhi-kun, and Zhu, Xiao-dong
- Published
- 2020
- Full Text
- View/download PDF
10. Exosomes overexpressing miR-34c inhibit malignant behavior and reverse the radioresistance of nasopharyngeal carcinoma
- Author
-
Wan, Fang-Zhu, Chen, Kai-Hua, Sun, Yong-Chu, Chen, Xi-Chan, Liang, Ren-Ba, Chen, Li, and Zhu, Xiao-Dong
- Published
- 2020
- Full Text
- View/download PDF
11. Emerging agents and regimens for hepatocellular carcinoma
- Author
-
Zhu, Xiao-Dong and Sun, Hui-Chuan
- Published
- 2019
- Full Text
- View/download PDF
12. Methanol extract of semen Ziziphi Spinosae attenuates ethanol withdrawal anxiety by improving neuropeptide signaling in the central amygdala
- Author
-
Li, Li Bo, Kim, Young Woo, Wang, Yu Hua, Bai, Li, Zhu, Xiao Dong, Zhao, Zheng Lin, Lee, Chul Won, Jiao, Yu, Wu, Tong, Cai, Zhen Zhen, Kim, Sang Chan, An, Won G., Yang, Chae Ha, Cui, Guang Cheng, and Zhao, Rong Jie
- Published
- 2019
- Full Text
- View/download PDF
13. Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
- Author
-
Cao, Man-Qing, You, A-Bin, Zhu, Xiao-Dong, Zhang, Wei, Zhang, Yuan-Yuan, Zhang, Shi-Zhe, Zhang, Kei-wei, Cai, Hao, Shi, Wen-Kai, Li, Xiao-Long, Li, Kang-Shuai, Gao, Dong-Mei, Ma, De-Ning, Ye, Bo-Gen, Wang, Cheng-Hao, Qin, Cheng-Dong, Sun, Hui-Chan, Zhang, Ti, and Tang, Zhao-You
- Published
- 2018
- Full Text
- View/download PDF
14. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells
- Author
-
Hu, Bo, Ding, Guang-Yu, Fu, Pei-Yao, Zhu, Xiao-Dong, Ji, Yuan, Shi, Guo-Ming, Shen, Ying-Hao, Cai, Jia-Bin, Yang, Zhen, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan, Kuang, Ming, and Huang, Cheng
- Published
- 2018
- Full Text
- View/download PDF
15. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
- Author
-
Cao, Man-Qing, You, A-Bin, Zhu, Xiao-Dong, Zhang, Wei, Zhang, Yuan-Yuan, Zhang, Shi-Zhe, Zhang, Ke-wei, Cai, Hao, Shi, Wen-Kai, Li, Xiao-Long, Li, Kang-Shuai, Gao, Dong-Mei, Ma, De-Ning, Ye, Bo-Gen, Wang, Cheng-Hao, Qin, Cheng-Dong, Sun, Hui-Chuan, Zhang, Ti, and Tang, Zhao-You
- Published
- 2018
- Full Text
- View/download PDF
16. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
- Author
-
Cheng Huang, Xiao-Dong Zhu, Yuan Ji, Guang-Yu Ding, Guo-Ming Shi, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Huang, Cheng, Zhu, Xiao-Dong, Ji, Yuan, Ding, Guang-Yu, Shi, Guo-Ming, Shen, Ying-Hao, Zhou, Jian, Fan, Jia, and Sun, Hui-Chuan
- Subjects
MICROCIRCULATION disorders ,LIVER cancer patients ,LIVER cancer ,COHORT analysis ,CANCER relapse ,SURVIVAL behavior (Animals) ,HEPATOCELLULAR carcinoma ,LIVER tumors ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,TUMOR classification ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Background: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage.Methods: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent curative surgery in the year of 2006 (validation cohort).Results: Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was associated with poor OS and RFS (P < 0.001 for both) in HCC patients at stage A, with poor OS in patients at stage 0 (P = 0.028), and with poor RFS at stage B (P = 0.039). In multivariate analysis, MVI was an independent risk factor for OS (HR = 1.431, 95% CI, 1.163-1.761, P < 0.001) and RFS (HR = 1.400, 95% CI, 1.150-1.705, P = 0.001) in patients at stage A; and an independent risk factor for RFS (P = 0.043) in patients at stage B. A similar clinical significance of MVI was found in the validation cohort.Conclusions: MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI was associated with patient survival and may help to select patients with high risk of disease recurrence. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. A new prognostic histopathologic classification of nasopharyngeal carcinoma
- Author
-
Wang, Hai-Yun, Chang, Yih-Leong, To, Ka-Fai, Hwang, Jacqueline S. G., Mai, Hai-Qiang, Feng, Yan-Fen, Chang, Ellen T., Wang, Chen-Ping, Kam, Michael Koon Ming, Cheah, Shie-Lee, Lee, Ming, Gao, Li, Zhang, Hui-Zhong, He, Jie-Hua, Jiang, Hao, Ma, Pei-Qing, Zhu, Xiao-Dong, Zeng, Liang, Chen, Chun-Yan, Chen, Gang, Huang, Ma-Yan, Fu, Sha, Shao, Qiong, Han, An-Jia, Li, Hai-Gang, Shao, Chun-Kui, Huang, Pei-Yu, Qian, Chao-Nan, Lu, Tai-Xiang, Li, Jin-Tian, Ye, Weimin, Ernberg, Ingemar, Ng, Ho Keung, Wee, Joseph T. S., Zeng, Yi-Xin, Adami, Hans-Olov, Chan, Anthony T. C., and Shao, Jian-Yong
- Subjects
Nasopharyngeal carcinoma ,Pathologic classification ,Prognosis - Abstract
Background: The current World Health Organization (WHO) classification of nasopharyngeal carcinoma (NPC) conveys little prognostic information. This study aimed to propose an NPC histopathologic classification that can potentially be used to predict prognosis and treatment response. Methods: We initially developed a histopathologic classification based on the morphologic traits and cell differentiation of tumors of 2716 NPC patients who were identified at Sun Yat-sen University Cancer Center (SYSUCC) (training cohort). Then, the proposed classification was applied to 1702 patients (retrospective validation cohort) from hospitals outside SYSUCC and 1613 patients (prospective validation cohort) from SYSUCC. The efficacy of radiochemotherapy and radiotherapy modalities was compared between the proposed subtypes. We used Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS). Results: The 5-year OS rates for all NPC patients who were diagnosed with epithelial carcinoma (EC; 3708 patients), mixed sarcomatoid-epithelial carcinoma (MSEC; 1247 patients), sarcomatoid carcinoma (SC; 823 patients), and squamous cell carcinoma (SCC; 253 patients) were 79.4%, 70.5%, 59.6%, and 42.6%, respectively (P < 0.001). In multivariate models, patients with MSEC had a shorter OS than patients with EC (HR = 1.44, 95% CI = 1.27–1.62), SC (HR = 2.00, 95% CI = 1.76–2.28), or SCC (HR = 4.23, 95% CI = 3.34–5.38). Radiochemotherapy significantly improved survival compared with radiotherapy alone for patients with EC (HR = 0.67, 95% CI = 0.56–0.80), MSEC (HR = 0.58, 95% CI = 0.49–0.75), and possibly for those with SCC (HR = 0.63; 95% CI = 0.40–0.98), but not for patients with SC (HR = 0.97, 95% CI = 0.74–1.28). Conclusions: The proposed classification offers more information for the prediction of NPC prognosis compared with the WHO classification and might be a valuable tool to guide treatment decisions for subtypes that are associated with a poor prognosis.
- Published
- 2016
- Full Text
- View/download PDF
18. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
- Author
-
Zhang, Ju-Bo, Sun, Hui-Chuan, Jia, Wei-Dong, Zhuang, Peng-Yuan, Qian, Yong-Bing, Zhu, Xiao-Dong, Kong, Ling-Qun, Wang, Lu, Wu, Wei-Zhong, and Tang, Zhao-You
- Subjects
LIVER cancer ,ADJUVANT treatment of cancer ,VASCULAR endothelial growth factors ,TUMORS ,APOPTOSIS ,NEOVASCULARIZATION - Abstract
Background: Postoperative interferon-α(IFN-α) treatment delays hepatocellular carcinoma(HCC) recurrence and prolongs patient survival, and may thus be an effective form of adjuvant therapy. However, clinical observations found that HCC recurs in some patients within 8 months of IFN-α treatment being discontinued. We investigated whether HCC regrowth appears after IFN-α is discontinued, whether re-initiated IFN-α is effective, and the underlying mechanisms of IFN-α treatment. Methods: The human HCC nude mouse model LCI-D20 was used to study the effects of IFN-α treatment, discontinued IFN-α treatment, and re-initiated IFN-α treatment on tumor growth. Tumor weight, microvessel density(MVD), serum vascular endothelial growth factor (VEGF), and tumor cell apoptosis were analyzed. Angiogenesis-related factors were studied using cDNA microarray in different tumor samples and confirmed using reverse transcription–polymerase chain reaction(RT-PCR) and Western blotting assays. Finally, imatinib was added with re-initiated IFN-α treatment to improve efficacy. Results: IFN-α (1.5×10
7 U/kg/day for 20 days) suppressed HCC growth by 60.3% and decreased MVD by 52.2% compared with the control. However, tumor regrowth occurred after IFN-α was discontinued, and re-initiated IFN-αtreatment was not effective for inhibiting tumor growth or reducing MVD compared with a saline-treated group. cDNA microarray showed VEGF was down-regulated while platelet-derived growth factor-A (PDGF-A) was up-regulated when IFN-α treatment was re-initiated. These findings were further confirmed with RT-PCR and Western blotting assay. The combination of imatinib with re-initiated IFN-α reduced HCC weight by 30.7% and decreased MVD by 31.1% compared with IFN-α treatment only (P=0.003 and 0.015, respectively). Conclusion: Tumor regrowth occurred after IFN-α treatment was discontinued. Re-initiated IFN-α treatment was not effective and was associated with up-regulation of PDGF-A, while the VEGF remained suppressed. The combination of a PDGF-receptor inhibitor with IFN-α improved the effect of the re-initiated treatment. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
19. Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.
- Author
-
Zhu, Xiao-Dong, Zhang, Yuan-Yuan, Zhang, Shi-Zhe, Cai, Hao, Shi, Wen-Kai, Li, Xiao-Long, Li, Kang-Shuai, Gao, Dong-Mei, Sun, Hui-Chan, Tang, Zhao-You, Cao, Man-Qing, Zhang, Wei, Zhang, Ti, You, A-Bin, Zhang, Kei-wei, Ma, De-Ning, Ye, Bo-Gen, Wang, Cheng-Hao, and Qin, Cheng-Dong
- Subjects
- *
CARCINOMA , *LIVER cancer - Abstract
The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
- Author
-
Huang C, Zhu XD, Ji Y, Ding GY, Shi GM, Shen YH, Zhou J, Fan J, and Sun HC
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular surgery, Child, Disease-Free Survival, Female, Humans, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Spain, Survival Analysis, Treatment Outcome, Young Adult, Carcinoma, Hepatocellular blood supply, Carcinoma, Hepatocellular pathology, Liver Neoplasms blood supply, Liver Neoplasms pathology
- Abstract
Background: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage., Methods: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent curative surgery in the year of 2006 (validation cohort)., Results: Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was associated with poor OS and RFS (P < 0.001 for both) in HCC patients at stage A, with poor OS in patients at stage 0 (P = 0.028), and with poor RFS at stage B (P = 0.039). In multivariate analysis, MVI was an independent risk factor for OS (HR = 1.431, 95% CI, 1.163-1.761, P < 0.001) and RFS (HR = 1.400, 95% CI, 1.150-1.705, P = 0.001) in patients at stage A; and an independent risk factor for RFS (P = 0.043) in patients at stage B. A similar clinical significance of MVI was found in the validation cohort., Conclusions: MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI was associated with patient survival and may help to select patients with high risk of disease recurrence.
- Published
- 2017
- Full Text
- View/download PDF
21. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
- Author
-
Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, Cao MQ, Gao DM, Sun HC, and Tang ZY
- Subjects
- Animals, Blotting, Western, Cadherins genetics, Cadherins metabolism, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Enhancer of Zeste Homolog 2 Protein, HEK293 Cells, Hep G2 Cells, Humans, Immunohistochemistry, Liver Neoplasms metabolism, Liver Neoplasms pathology, Male, Mice, Inbred BALB C, Mice, Nude, Polycomb Repressive Complex 2 metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transplantation, Heterologous, Carcinoma, Hepatocellular genetics, Epithelial-Mesenchymal Transition genetics, Gene Expression Regulation, Neoplastic, Liver Neoplasms genetics, MicroRNAs genetics, Polycomb Repressive Complex 2 genetics
- Abstract
Background: Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC). The direct roles of miR-26a on tumor cell invasion remain poorly understood. In this study, we aim to explore the mechanism of miR-26a in modulating epithelial-mesenchymal transition (EMT) in HCC., Methods: In vitro cell morphology and cell migration were compared between the hepatoma cell lines HCCLM3 and HepG2, which were established in the previous study. Overexpression and down-regulation of miR-26a were induced in these cell lines, and Western blot and immunofluorescence assays were used to detect the expression of EMT markers. Xenograft nude mouse models were used to observe tumor growth and pulmonary metastasis. Immunohistochemical assays were conducted to study the relationships between miR-26a expression and enhancer of zeste homolog 2 (EZH2) and E-cadherin expression in human HCC samples., Results: Down-regulation of miR-26a in HCCLM3 and HepG2 cells resulted in an EMT-like cell morphology and high motility in vitro and increased in tumor growth and pulmonary metastasis in vivo. Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression, miR-26a inhibited the EMT process in vitro and in vivo. Luciferase reporter assay showed that miR-26a directly interacted with EZH2 messenger RNA (mRNA). Furthermore, the expression of miR-26a was positively correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue., Conclusions: miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression.
- Published
- 2016
- Full Text
- View/download PDF
22. microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma.
- Author
-
Chai ZT, Zhu XD, Ao JY, Wang WQ, Gao DM, Kong J, Zhang N, Zhang YY, Ye BG, Ma DN, Cai H, and Sun HC
- Subjects
- Animals, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Down-Regulation, Humans, Liver Neoplasms pathology, Macrophages, Mice, Phosphatidylinositol 3-Kinases metabolism, Carcinoma, Hepatocellular genetics, Liver Neoplasms genetics, Macrophage Colony-Stimulating Factor metabolism, MicroRNAs genetics
- Abstract
Background: microRNAs (miRNAs) have been reported to modulate macrophage colony-stimulating factor (M-CSF) and macrophages. The aim of this study was to find whether miR-26a can suppress M-CSF expression and the recruitment of macrophages., Methods: Hepatocellular carcinoma (HCC) cell lines with decreased or increased expression of miR-26a were established in a previous study. M-CSF expression by tumor cells was measured by enzyme-linked immunosorbent assay, and cell migration assays were used to explore the effect of HCC cell lines on macrophage recruitment in vitro. Real-time PCR measured a panel of mRNAs expressed by macrophages. Xenograft models were used to observe tumor growth. Immunohistochemistry was conducted to study the relation between miR-26a expression and M-CSF expression and macrophage recruitment in patients with HCC., Results: Ectopic expression of miR-26a reduced expression of M-CSF. The conditioned medium (CM) from HepG2 cells that overexpressed miR-26a reduced the migration ability of THP-1 cells stimulated by phorbol myristate acetate (PMA) increased expression of interleukin (IL)-12b or IL-23 mRNA and decreased expression of chemokine (C-C motif) ligand (CCL)22, CCL17, and IL-10 mRNA, in comparison to the medium from the parental HepG2 cells. These effects could be interrupted by the PI3K/Akt pathway inhibitor LY294002. Ectopic expression of miR-26a in HCC cells suppressed tumor growth, M-CSF expression, and infiltration of macrophages in tumors. Similar results were also found when using HCCLM3 cells. Furthermore, the expression of miR-26a was inversely correlated with M-CSF expression and macrophage infiltration in tumor tissues from patients with HCC., Conclusions: miR-26a expression reduced M-CSF expression and recruitment of macrophages in HCC.
- Published
- 2015
- Full Text
- View/download PDF
23. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
- Author
-
Zhang KZ, Zhang QB, Zhang QB, Sun HC, Ao JY, Chai ZT, Zhu XD, Lu L, Zhang YY, Bu Y, Kong LQ, and Tang ZY
- Subjects
- AC133 Antigen, Animals, Arsenic Trioxide, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Cell Differentiation drug effects, Cell Line, Tumor, Disease Models, Animal, Down-Regulation, Humans, Liver Neoplasms metabolism, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Neoplastic Stem Cells pathology, Random Allocation, Signal Transduction, Survival Analysis, Transcription Factors genetics, Xenograft Model Antitumor Assays, Zinc Finger Protein GLI1, Antigens, CD metabolism, Arsenicals pharmacology, Carcinoma, Hepatocellular drug therapy, Glycoproteins metabolism, Liver Neoplasms drug therapy, Oxides pharmacology, Peptides metabolism, Transcription Factors biosynthesis
- Abstract
Background: Cancer stem cells (CSCs) play a key role in the posthepatectomy recurrence of hepatocellular carcinoma (HCC). CD133+ HCC cells exhibit liver CSC-like properties, and CSC differentiation-inducing therapy may lead these cells to lose their self-renewal ability and may induce terminal differentiation, which may in turn allow their malignant potential to be controlled. Because arsenic trioxide (As₂O₃) increases remission rates and prolongs survival among patients with acute promyelocytic leukemia by inducing differentiation and apoptosis of leukemic cells, we hypothesized that As₂O₃ might also inhibit HCC recurrence and prolong survival time after hepatectomy by inducing differentiation of HCC CSCs., Methods: We evaluated the As₂O₃ induced differentiation of human HCC CSCs and its mechanism in vitro, and we investigated the effects of treatment with As₂O₃ on recurrence rates and median survival in a mouse xenograft model., Results: We found that As₂O₃ induced HCC CSC differentiation by down-regulating the expression of CD133 and some stemness genes, thus inhibiting the cells' self-renewal ability and tumorigenic capacity without inhibiting their proliferation in vitro. In vivo experiments indicated that As₂O₃ decreased recurrence rates after radical resection and prolonged survival in a mouse model. As₂O₃, which shows no apparent toxicity, may induce HCC CSC differentiation by down-regulating the expression of GLI1., Conclusions: We found that As₂O₃ induced HCC CSC differentiation, inhibited recurrence, and prolonged survival after hepatectomy by targeting GLI1expression. Our results suggest that the clinical safety and utility of As₂O₃ should be further evaluated.
- Published
- 2014
- Full Text
- View/download PDF
24. Role of chemotherapy in stage IIb nasopharyngeal carcinoma.
- Author
-
Pan XB and Zhu XD
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Chemotherapy, Adjuvant, Cisplatin administration & dosage, Fluorouracil administration & dosage, Humans, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms pathology, Neoadjuvant Therapy, Neoplasm Staging, Radiotherapy, Intensity-Modulated, Chemoradiotherapy, Nasopharyngeal Neoplasms therapy
- Abstract
The efficacy of neoadjuvant chemotherapy and adjuvant chemotherapy on stage IIb nasopharyngeal carcinoma(NPC) remains unclear. Conventional two-dimensional radiotherapy combined with concurrent chemotherapy can improve the overall survival, progression-free survival, recurrence-free survival, and distant metastasis-free survival of patients with stage IIb NPC. Intensity-modulated radiotherapy without concurrent chemotherapy also provides good outcomes for patients with stage IIb NPC. This article summarizes the features of stage IIb NPC and reviews the role of chemotherapy in this subgroup of NPC.
- Published
- 2012
- Full Text
- View/download PDF
25. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization.
- Author
-
Wang WQ, Liu L, Sun HC, Fu YL, Xu HX, Chai ZT, Zhang QB, Kong LQ, Zhu XD, Lu L, Ren ZG, and Tang ZY
- Subjects
- Animals, Antineoplastic Agents, Phytogenic administration & dosage, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Cell Growth Processes drug effects, Cell Line, Tumor, Humans, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Metastasis, Random Allocation, Xenograft Model Antitumor Assays, Abietanes pharmacology, Antineoplastic Agents, Phytogenic therapeutic use, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
Background: Promotion of endothelial normalization restores tumor oxygenation and obstructs tumor cells invasion, intravasation, and metastasis. We therefore investigated whether a vasoactive drug, tanshinone IIA, could inhibit metastasis by inducing vascular normalization after palliative resection (PR) of hepatocellular carcinoma (HCC)., Methods: A liver orthotopic double-tumor xenograft model in nude mouse was established by implantation of HCCLM3 (high metastatic potential) and HepG2 tumor cells. After removal of one tumor by PR, the effects of tanshinone IIA administration on metastasis, tumor vascularization, and survival were evaluated. Tube formation was examined in mouse tumor-derived endothelial cells (TECs) treated with tanshinone IIA., Results: PR significantly accelerated residual hepatoma metastases. Tanshinone IIA did not inhibit growth of single-xenotransplanted tumors, but it did reduce the occurrence of metastases. Moreover, it inhibited PR-enhanced metastases and, more importantly, prolonged host survival. Tanshinone IIA alleviated residual tumor hypoxia and suppressed epithelial-mesenchymal transition (EMT) in vivo; however, it did not downregulate hypoxia-inducible factor 1α (HIF-1α) or reverse EMT of tumor cells under hypoxic conditions in vitro. Tanshinone IIA directly strengthened tube formation of TECs, associated with vascular endothelial cell growth factor receptor 1/platelet derived growth factor receptor (VEGFR1/PDGFR) upregulation. Although the microvessel density (MVD) of residual tumor tissue increased after PR, the microvessel integrity (MVI) was still low. While tanshinone IIA did not inhibit MVD, it did dramatically increase MVI, leading to vascular normalization., Conclusions: Our results demonstrate that tanshinone IIA can inhibit the enhanced HCC metastasis associated with PR. Inhibition results from promoting VEGFR1/PDGFR-related vascular normalization. This application demonstrates the potential clinical benefit of preventing postsurgical recurrence.
- Published
- 2012
- Full Text
- View/download PDF
26. Comparison between two pedicle screw augmentation instrumentations in adult degenerative scoliosis with osteoporosis.
- Author
-
Xie Y, Fu Q, Chen ZQ, Shi ZC, Zhu XD, Wang CF, and Li M
- Subjects
- Absorptiometry, Photon, Adult, Aged, Bone Cements adverse effects, Bone Density, China, Disability Evaluation, Equipment Design, Female, Humans, Lumbar Vertebrae diagnostic imaging, Lumbar Vertebrae pathology, Male, Middle Aged, Osteoporosis diagnosis, Polymethyl Methacrylate adverse effects, Retrospective Studies, Scoliosis complications, Scoliosis diagnosis, Spinal Fusion adverse effects, Time Factors, Treatment Outcome, Bone Cements therapeutic use, Bone Screws, Bone Transplantation adverse effects, Lumbar Vertebrae surgery, Osteoporosis complications, Polymethyl Methacrylate therapeutic use, Scoliosis surgery, Spinal Fusion instrumentation
- Abstract
Background: The operative treatment of adult degenerative scoliosis combined with osteoporosis increase following the epidemiological development. Studies have confirmed that screws in osteoporotic spines have significant lower-screw strength with more frequent screw movements within the vertebra than normal spines. Screws augmented with polymethylmethacrylate (PMMA) or with autogenous bone can offer more powerful corrective force and significant advantages., Methods: A retrospective analysis was conducted on 31 consecutive patients with degenerative lumbar scoliosis combined with osteoporosis who had surgery from December 2000. All had a minimum of 2-year follow-up. All patients had posterior approach surgery. 14 of them were fixed with pedicle screw by augmentation with polymethylmethacrylate (PMMA) and the other 17 patients with autogenous bone. Age, sex and whether smoking were similar between the two groups. Surgical time, blood loss, blood transfusion, medical cost, post surgery ICU time, hospital day, length of oral pain medicines taken, Pre-and postoperative Oswestry disability index questionnaire and surgical revision were documented and compared. Preoperative, postoperative and final follow up Cobb angle, sagittal lumbar curve, correction rate, and Follow up Cobb loss were also compared., Results: No significant differences were found between the autogenous bone group and polymethylmethacrylate group with regards to all the targets above except for length of oral pain medicines taken and surgery cost. 2 patients were seen leakage during operation, but there is neither damage of nerve nor symptom after operation. No revision was needed., Conclusion: Both augmentation pedicle screw with polymethylmethacrylate (PMMA) and autogenous bone treating degenerative lumbar scoliosis combined with osteoporosis can achieve a good surgical result. Less oral pain medicines taken are the potential benefits of polymethylmethacrylate augmentation, but that is at the cost of more medical spending.
- Published
- 2011
- Full Text
- View/download PDF
27. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
- Author
-
Zhu XD, Zhang JB, Fan PL, Xiong YQ, Zhuang PY, Zhang W, Xu HX, Gao DM, Kong LQ, Wang L, Wu WZ, Tang ZY, Ding H, and Sun HC
- Subjects
- Animals, Apoptosis drug effects, Blood Vessels drug effects, Blood Vessels pathology, Carcinoma, Hepatocellular diagnostic imaging, Carcinoma, Hepatocellular pathology, Cell Line, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cells, Cultured, Dose-Response Relationship, Drug, Hep G2 Cells, Humans, Image Enhancement, Indazoles, Liver Neoplasms, Experimental diagnostic imaging, Liver Neoplasms, Experimental pathology, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Tumor Burden drug effects, Ultrasonography methods, Angiogenesis Inhibitors pharmacology, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms, Experimental drug therapy, Pyrimidines pharmacology, Sulfonamides pharmacology, Xenograft Model Antitumor Assays
- Abstract
Background: Antiangiogenesis is a promising therapy for advanced hepatocellular carcinoma (HCC), but the effects are difficult to be evaluated. Pazopanib (GW786034B) is a pan-vascular endothelial growth factor receptor inhibitor, the antitumor effects or antiangiogenic effects haven't been investigated in HCC., Methods: In vitro direct effects of pazopanib on human HCC cell lines and endothelial cells were evaluated. In vivo antitumor effects were evaluated in three xenograft nude mice models. In the subcutaneous HCCLM3 model, intratumoral blood perfusion was detected by contrast-enhanced ultrasonography (CEUS), and serial quantitative parameters were profiled from the time-intensity curves of ultrasonograms., Results: In vitro proliferation of various HCC cell lines were not inhibited by pazopanib. Pazopanib inhibited migration and invasion and induced apoptosis significantly in two HCC cell lines, HCCLM3 and PLC/PRF/5. Proliferation, migration, and tubule formation of human umbilical vein endothelial cells were inhibited by pazopanib in a dose-dependent manner. In vivo tumor growth was significantly inhibited by pazopanib in HCCLM3, HepG2, and PLC/PRF/5 xenograft models. Various intratumoral perfusion parameters changed over time, and the signal intensity was significantly impaired in the treated tumors before the treatment efficacy on tumor size could be observed. Mean transit time of the contrast media in hotspot areas of the tumors was reversely correlated with intratumoral microvessel density., Conclusions: Antitumor effects of pazopanib in HCC xenografts may owe to its antiangiogenic effects, and the in vivo antiangiogenic effects could be evaluated by quantitative CEUS.
- Published
- 2011
- Full Text
- View/download PDF
28. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.
- Author
-
Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L, Wang WQ, and Tang ZY
- Subjects
- Animals, Blotting, Western, Carcinoma, Hepatocellular secondary, Cell Movement drug effects, Cell Proliferation drug effects, Cell Survival drug effects, Cell Transdifferentiation drug effects, Fluorescent Antibody Technique, Hep G2 Cells, Humans, Immunohistochemistry, Liver Neoplasms pathology, Lung Neoplasms secondary, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Invasiveness, Neoplasm, Residual secondary, Oxaliplatin, Time Factors, Tumor Burden, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Antineoplastic Agents, Phytogenic pharmacology, Carcinoma, Hepatocellular drug therapy, Drugs, Chinese Herbal pharmacology, Liver Neoplasms drug therapy, Lung Neoplasms drug therapy, Neoplasm, Residual drug therapy, Organoplatinum Compounds pharmacology
- Abstract
Background: The opposite effects of chemotherapy, which enhance the malignancy of treated cancers such as hepatocellular carcinoma (HCC), are not well understood. We investigated this phenomenon and corresponding mechanisms to develop a novel approach for improving chemotherapy efficacy in HCC., Methods: Human hepatocellular carcinoma cell lines HepG2 (with low metastatic potential) and MHCC97L (with moderate metastatic potential) were used for the in vitro study. An orthotopic nude mouse model of human HCC was developed using MHCC97L cells. We then assessed the metastatic potential of surviving tumor cells after in vitro and in vivo oxaliplatin treatment. The molecular changes in surviving tumor cells were evaluated by western blot, immunofluorescence, and immunohistochemistry. The Chinese herbal extract Songyou Yin (composed of five herbs) was investigated in vivo to explore its effect on the metastatic potential of oxaliplatin-treated cancer cells., Results: MHCC97L and HepG2 cells surviving oxaliplatin treatment showed enhanced migration and invasion in vitro. Residual HCC after in vivo oxaliplatin treatment demonstrated significantly increased metastasis to the lung (10/12 vs. 3/12) when re-inoculated into the livers of new recipient nude mice. Molecular changes consistent with epithelial-mesenchymal transition (EMT) were observed in oxaliplatin-treated tumor tissues and verified by in vitro experiments. The Chinese herbal extract Songyou Yin (4.2 and 8.4 g/kg) attenuated EMT and inhibited the enhanced metastatic potential of residual HCC in nude mice (6/15 vs. 13/15 and 3/15 vs. 13/15, respectively)., Conclusions: The surviving HCC after oxaliplatin treatment underwent EMT and demonstrated increased metastatic potential. Attenuation of EMT by Songyou Yin may improve the efficacy of chemotherapy in HCC.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.